Journal article
Srila H Chadalavada, Jacqueline K Shaia, M. Russell, Katherine E. Talcott, Rishi P. Singh
Ophthalmic Surgery Lasers and Imaging Retina, 2023
Ophthalmic Surgery Lasers and Imaging Retina, 2023
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Chadalavada, S. H., Shaia, J. K., Russell, M., Talcott, K. E., & Singh, R. P. (2023). Impact of Dyslipidemia Medications on the Prevalence of Diabetic Retinopathy Among a Large US Cohort. Ophthalmic Surgery Lasers and Imaging Retina.
Chicago/Turabian
Click to copy
Chadalavada, Srila H, Jacqueline K Shaia, M. Russell, Katherine E. Talcott, and Rishi P. Singh. “Impact of Dyslipidemia Medications on the Prevalence of Diabetic Retinopathy Among a Large US Cohort.” Ophthalmic Surgery Lasers and Imaging Retina (2023).
MLA
Click to copy
Chadalavada, Srila H., et al. “Impact of Dyslipidemia Medications on the Prevalence of Diabetic Retinopathy Among a Large US Cohort.” Ophthalmic Surgery Lasers and Imaging Retina, 2023.
BibTeX Click to copy
@article{srila2023a,
title = {Impact of Dyslipidemia Medications on the Prevalence of Diabetic Retinopathy Among a Large US Cohort.},
year = {2023},
journal = {Ophthalmic Surgery Lasers and Imaging Retina},
author = {Chadalavada, Srila H and Shaia, Jacqueline K and Russell, M. and Talcott, Katherine E. and Singh, Rishi P.}
}
Abstract
BACKGROUND AND OBJECTIVE Dyslipidemia medications such as statins and fibrates may be associated with a reduction in diabetic retinopathy (DR) progression, but real-world data is lacking. This study evaluates cholesterol-lowering medications and their association with the prevalence of DR and advanced DR complications.
PATIENTS AND METHODS Data was collected using codes from the International Classification of Diseases on TriNetX, a cross-sectional database of over 79 million Americans, between June and August 2022. Prevalence and prevalence odds ratios (POR) were calculated.
RESULTS Patients taking pitavastatin (OR 0.64, 95% CI 0.49, 0.84), fenofibrate (OR 0.83, CI 0.79, 0.87), or evolocumab (OR 0.80, CI 0.68, 0.95) had lower POR of proliferative DR compared to nonproliferative DR. Patients taking any cholesterol medication had a lower POR of vitreous hemorrhage. Patients taking fibrates also had lower POR of neovascular glaucoma.
CONCLUSION This exploratory study highlights positive associations between DR and dyslipidemia and medications that may have fewer worsening events in DR patients. [Ophthalmic Surg Lasers Imaging Retina 2023;54:626-633.].